PMC9639782_01
HER2 (A), PD-L1 (B), and EBER (C) staining of the primary tumor. Scale bars: 50 microm.
fimmu-13-1003859-g001.jpg
PMC9639782_01_fimmu-13-1003859-g001.jpg
f1
The immunohistochemistry indicated that HER-2 and PD-L1 were overexpressed ( Figures 1A, B ). Meanwhile, an EBV-encoded RNA (EBER) assay showed positive staining parallel to the tumor harboring EBV infection ( Figure 1C ).
Computed tomography with contrast showing the patient's lesions before and after PD-1 inhibitor treatment. The lesions in lesser gastric curvature (A), left front of the gastric body (B), right lobe of the liver (C) and right adrenal (D). Patients were treated with a PD-1 inhibitor from December 2017.
fimmu-13-1003859-g002.jpg
PMC9639782_01_fimmu-13-1003859-g002.jpg
f2
On January 25 and March 27, 2018, CT scans (with contrast) showed a partial response and a steadily shrinking of the known lesions, including the lesser gastric curvature ( Figure 2A ), left front of the gastric body ( Figure 2B ), right lobe of the liver ( Figure 2C ) and right adrenal ( Figure 2D ), but still in TNM stage IV.  Figure 2B  also showed that the new bilateral pleural effusion (2017-9-9) was completely absorbed after nivolumab treatment.
The management of nivolumab-related exfoliative dermatitis eruption.
fimmu-13-1003859-g003.jpg
PMC9639782_01_fimmu-13-1003859-g003.jpg
f3
Exfoliative dermatitis eruption was developed on his lower extremities and palmoplantar ( Figure 3 ) after 40 days of PD-1 inhibitor treatment.
Dynamics of cancer antigen 19-9/125 levels during the entire disease course. T, Trastuzumab; DCS, docetaxel + cisplatin+S-1; FOLFIRI, folinic acid + fluorouracil + irinotecan.
fimmu-13-1003859-g004.jpg
PMC9639782_01_fimmu-13-1003859-g004.jpg
f4
Figure 4  displayed the trajectories of two tumor biomarkers during the whole period of therapy.